Resources
82 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 4/12/2024
This peer reviewed journal article OUD treatment and pregnancy outcomes among pregnant patients receiving OUD care through a telehealth addiction treatment program in the US. The patients identified in the study received buprenorphine or buprenorphine and naloxone treatment.
Posted 3/29/2024
The Centers for Disease Control and Prevention (CDC) has naloxone trainings and fact sheets available for clinicians. The trainings and fact sheets can help clinicians raise awareness about the benefits of naloxone by talking with patients and their family, friends, and caregivers.
Posted 3/10/2024 (updated 3/28/2024)
The Substance Abuse and Mental Health Services Administration's (SAMHSA) updated Overdose Prevention and Response Toolkit provides guidance to a wide range of individuals on preventing and responding to an overdose. It emphasizes harm reduction and access to treatment as essential aspects of overdose prevention.
Posted 1/19/2024 (updated 3/28/2024)
The FDA announced that the manufacturer of NARCAN 4 mg Nasal Spray products, Emergent BioSolutions, has extended the shelf-life of their product from 3 years to 4 years. This new extension of shelf-life was requested by the FDA to help prevent overdoses and reduce overdose-related deaths.
Posted 10/23/2023 (updated 3/27/2024)
Posted 9/29/2023 (updated 3/27/2024)
The 2023 RCORP-Overdose Response Onboarding Packet contains strategies and resources to assist grantees in the implementation of your new Overdose Response (OR) grant. The Onboarding Packet includes tools to support grant-funded activities, along with information on accessing TA.
Posted 8/25/2023 (updated 3/26/2024)
As HIV transmission via injection drugs are increasing, knowing the variation in which the the transmission occurs can be beneficial in treatment and intervention. Authors of the study look into the frequency and distribution of HIV transmission behaviors among people who use drugs in rural areas to possibly determine if interventions could be universally effective. Data collected in the study suggests that there are many variations in the transmission behaviors.
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.
Posted 7/28/2023 (updated 3/26/2024)
The Rural Health Information Hub's (RHIhub) article covers best practices and emerging models for rural harm reduction programs. Among those featured in the article is the RCORP-TA grantee, the South Dakota State University's program Stigma, Treatment, Avoidance and Recovery in Time - South Dakota (START-SD).
RSV 2023 Session: Quick Response Teams: Preventing Deaths While Sharing the Hope of Recovery (Day 1)
Posted 7/26/2023 (updated 3/28/2024)
The presentation discussed the development and changes in the utilization of a Quick Response Team in an Ohio rural community.